Study on Sgc8 aptamer-mediated nucleic acid nanomaterial-doxorubicin complex for tumor targeted therapy. 2023

Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, Department of Cell Biology and Medical Genetics, College of Laboratory Medicine and Life sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, PR China; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325088, PR China.

Chemotherapy is one of the most important treatments for malignant cancers, but most chemotherapeutic drugs are poorly targeted, highly toxic and expensive, resulting in unsatisfactory treatment results for cancer patients. Therefore, intelligent drug delivery platforms are needed to be explored urgently to enhance drug treatment and reduce toxicity on normal cells. Nucleic acid nanomaterials are a class of nanomaterials developed on the basis of the "base complementary pairing principle", which have the advantages of good programmability, high stability, good biocompatibility, and strong targeting. Herein, we present a simple Sgc8 aptamer-modified nucleic acid nanomaterial (Sgc8NM) for the targeted delivery of Doxorubicin (Dox), a widely used chemotherapy drug in clinic. Studies have shown the Sgc8NM-Dox performed a precise treatment effect on target cells and low toxicity on non-target cells, providing a new strategy for the potential application of nanocomposite drugs in targeted cancer delivery.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009696 Nucleic Acids High molecular weight polymers containing a mixture of purine and pyrimidine nucleotides chained together by ribose or deoxyribose linkages. Nucleic Acid,Acid, Nucleic,Acids, Nucleic
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049329 Nanostructures Materials which have structured components with at least one dimension in the range of 1 to 100 nanometers. These include NANOCOMPOSITES; NANOPARTICLES; NANOTUBES; and NANOWIRES. Nanomaterials,Nanostructured Materials,Material, Nanostructured,Materials, Nanostructured,Nanomaterial,Nanostructure,Nanostructured Material
D052157 Aptamers, Nucleotide Nucleotide sequences, generated by iterative rounds of SELEX APTAMER TECHNIQUE, that bind to a target molecule specifically and with high affinity. DNA Aptamer,DNA Aptamers,RNA Aptamers,Rna Aptamer,Nucleotide Aptamers,Oligonucleotide Ligands, DNA,Oligonucleotide Ligands, RNA,Aptamer, DNA,Aptamer, Rna,Aptamers, DNA,Aptamers, RNA,DNA Oligonucleotide Ligands,RNA Oligonucleotide Ligands

Related Publications

Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
January 2015, ChemMedChem,
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
February 2023, Cancers,
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
June 2023, Journal of nanobiotechnology,
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
November 2021, Journal of controlled release : official journal of the Controlled Release Society,
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
April 2018, Nanomedicine : nanotechnology, biology, and medicine,
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
June 2021, ACS applied materials & interfaces,
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
January 2011, Methods in molecular biology (Clifton, N.J.),
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
February 2017, Macromolecular bioscience,
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
September 2009, Macromolecular bioscience,
Xuemei Hu, and Jing Zhang, and Qi Xiang, and Guoqiao Huang, and Quan Yuan, and Yuzhe Wang, and Zhifa Shen
September 2022, Nanomedicine : nanotechnology, biology, and medicine,
Copied contents to your clipboard!